CAJ | 학술논문

目的分析多沙唑嗪与阿替洛尔、特拉唑嗪对照治疗高血压有效性.方法检索PubMed、EMbase、The Cochrane Central Register of Controlled Trials (CENTRAL)、Medline、中国期刊全文数据库(CNKI)、维普中文科技期刊数据库(VIP)和万方医学数据库等,检索时间从1950年12月至2013年12月.根据纳入与排除标准,收集多沙唑嗪和阿替洛尔、特拉唑嗪对照治疗高血压随机对照试验(RCT)的研究,由2位评价员按Cochrane系统评价,独立进行资料提取、质量评价并交叉核对后,采用RevMan5.2软件进行Meta分析.结果共10个临床研究符合纳入标准,其中513例患者接受多沙唑嗪治疗,147例患者接受阿替洛尔治疗,353例患者接受特拉唑嗪治疗.Meta分析结果显示,阿替洛尔降低患者坐位舒张压[均数差(MD)=2.35,95％置信区间(CI):0.47 ～4.23,P=0.00]、坐位收缩压(MD =4.69,95％ CI:2.05 ～ 7.33,P=0.000)、坐位心率(MD=8.96,95％CI:6.21 ～ 11.71,P＜0.00)及站位心率(MD=10.74,95％ CI:8.29 ～13.19,P＜0.01)的作用优于多沙唑嗪.二者对改善患者的站位舒张压(MD=-0.15,95％CI:-2.53～2.22,P=0.90)与站位收缩压(MD =0.61,95％ CI:-2.32 ～3.54,P=0.66)差异无统计学意义.多沙唑嗪与特拉唑嗪对改善患者的坐位收缩压(MD=-0.43,95％ CI:-3.51 ～ 2.65,P=0.79)、坐位舒张压(MD=-0.39,95％CI-1.66 ～0.89,P=0.55)和坐位心率(MD=1.14,95％ CI:-1.02 ～3.30,P=0.30)的作用差异无统计学意义.结论多沙唑嗪在改善患者坐位血压、心率方面差于阿替洛尔,而与特拉唑嗪相似.对患者站位血压的影响与阿替洛尔相似.
목적 분석다사서진여아체락이、특랍서진대조치료고혈압유효성.방법 검색PubMed、EMbase、The Cochrane Central Register of Controlled Trials (CENTRAL)、Medline、중국기간전문수거고(CNKI)、유보중문과기기간수거고(VIP)화만방의학수거고등,검색시간종1950년12월지2013년12월.근거납입여배제표준,수집다사서진화아체락이、특랍서진대조치료고혈압수궤대조시험(RCT)적연구,유2위평개원안Cochrane계통평개,독립진행자료제취、질량평개병교차핵대후,채용RevMan5.2연건진행Meta분석.결과 공10개림상연구부합납입표준,기중513례환자접수다사서진치료,147례환자접수아체락이치료,353례환자접수특랍서진치료.Meta분석결과현시,아체락이강저환자좌위서장압[균수차(MD)=2.35,95％치신구간(CI):0.47 ～4.23,P=0.00]、좌위수축압(MD =4.69,95％ CI:2.05 ～ 7.33,P=0.000)、좌위심솔(MD=8.96,95％CI:6.21 ～ 11.71,P＜0.00)급참위심솔(MD=10.74,95％ CI:8.29 ～13.19,P＜0.01)적작용우우다사서진.이자대개선환자적참위서장압(MD=-0.15,95％CI:-2.53～2.22,P=0.90)여참위수축압(MD =0.61,95％ CI:-2.32 ～3.54,P=0.66)차이무통계학의의.다사서진여특랍서진대개선환자적좌위수축압(MD=-0.43,95％ CI:-3.51 ～ 2.65,P=0.79)、좌위서장압(MD=-0.39,95％CI-1.66 ～0.89,P=0.55)화좌위심솔(MD=1.14,95％ CI:-1.02 ～3.30,P=0.30)적작용차이무통계학의의.결론 다사서진재개선환자좌위혈압、심솔방면차우아체락이,이여특랍서진상사.대환자참위혈압적영향여아체락이상사.
Objective To evaluate the protective effect of doxazosin versus atenolol or terlazosinazole on essential hypertension.Methods Database was collected from CENTRAL,Pubmed,Medline,Embase,CNKI,VIP and Wanfang from December 1950 to December 2013.Randomized controlled trials (RCT) on doxazosin versus atenolol or terlazosinazole treating essential hypertension were collected according to predefined inclusion and exclusion criteria.According to the Cochrane method by two reviewers independently,following the quality evaluation and cross-check,the mcta-analyses were conducted using RevMan 5.2 software.Results A total of ten studies included 513 patients receiving doxazosin treatment,147 patients receiving atenolol treatment and 353 patients receiving terazosin treatment.In atenolol group,diastolic blood pressure (DBP) (MD =2.35,95％ CI:0.47-4.23,P =0.004) 、sitting systolic blood pressure (SBP) (MD =4.69,95 ％ CI:2.05-7.33,P =0.0005),sitting heart rate (HR) (MD =8.96,95 ％ CI:6.21-11.71,P ＜ 0.00001) and standing HR (MD =10.74,95 ％ CI:8.29-13.19,P ＜ 0.01) were all better than those in doxazosin group.Standing DBP(MD =-0.15,95％ CI:-2.53-2.22,P =0.90) and standing SBP(MD =0.61,95％ CI:-2.32-3.54,P =0.66) were not statistically different.Both doxazosin and terlazosin improved sitting SBP (MD =-0.43,95％ CI:-3.51-2.65,P =0.79) 、sitting DBP (MD =-0.39,95 ％ CI:-1.66-0.89,P =0.55) and sitting HR (MD =1.14,95％ CI:-1.02-3.30,P =0.30),which was not statistically significant.Conclusion Effect of Doxazosin on the sitting HR and blood pressure is inferior to atenolol but similar to terlazosin; Doxazosin is similar to atenolol regarding controlling standing blood pressure.